Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases
about
Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre studyEarly inflammatory markers in elicitation of allergic contact dermatitisT Cell Migration in Rheumatoid ArthritisConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsNanomedicine delivers promising treatments for rheumatoid arthritisTargeting leukocyte integrins in human diseasesTrafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cellsSmall-molecule inhibitors of protein-protein interactions: progressing towards the dreamA small molecule agonist of an integrin, alphaLbeta2.Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss.Differential role of ICAM ligands in determination of human memory T cell differentiationEffects of CD70 and CD11a in immune thrombocytopenia patients.Combinatorial libraries against libraries for selecting neoepitope activation-specific antibodies.Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNSDiscovery of very late antigen-4 (VLA-4, alpha4beta1 integrin) allosteric antagonists.The N-terminal domain of Nogo-A inhibits cell adhesion and axonal outgrowth by an integrin-specific mechanism.A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors.FRET based quantification and screening technology platform for the interactions of leukocyte function-associated antigen-1 (LFA-1) with intercellular adhesion molecule-1 (ICAM-1).Affinity of the alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma.ICAM-1 as a molecular target for triple negative breast cancerHypomethylation and overexpression of ITGAL (CD11a) in CD4(+) T cells in systemic sclerosis.FRET detection of lymphocyte function-associated antigen-1 conformational extension.Crevicular fluid levels of interleukin-8, interleukin-17 and soluble intercellular adhesion molecule-1 after regenerative periodontal therapy.Real-time analysis of the inside-out regulation of lymphocyte function-associated antigen-1 revealed similarities to and differences from very late antigen-4.Activation of AMP-activated protein kinase attenuates hepatocellular carcinoma cell adhesion stimulated by adipokine resistin.CD18 deficiency protects against multiple low-dose streptozotocin-induced diabetes.Expression and targeting of lymphocyte function-associated antigen 1 (LFA-1) on white blood cells for treatment of allergic asthma.Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection.The pathology and pathogenesis of retinal vasculitis.Selectively targeting T- and B-cell lymphomas: a benzothiazole antagonist of alpha4beta1 integrin.Modulation of radiation injury response in retinal endothelial cells by quinic acid derivative KZ-41 involves p38 MAPK.Halogenated benzimidazole carboxamides target integrin alpha4beta1 on T-cell and B-cell lymphomas.Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice.Mechanisms of dendritic cell trafficking across the blood-brain barrier.Modulation of the innate immune response within the periodontium.Methotrexate (MTX)-cIBR conjugate for targeting MTX to leukocytes: conjugate stability and in vivo efficacy in suppressing rheumatoid arthritis.Glycoengineering of HCELL, the human bone marrow homing receptor: sweetly programming cell migrationSoluble Vascular Cell Adhesion Molecule-1 (VCAM-1) as a Biomarker in the Mouse Model of Experimental Autoimmune Myocarditis (EAM)Lymphocyte trafficking to inflamed skin--molecular mechanisms and implications for therapeutic target molecules.Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization
P2860
Q22000875-B983F471-8EC0-4219-A694-035C8B164AA1Q24531952-5B09F75E-62EA-47D4-95CB-06DDB66C77EBQ26797338-931F8D88-87CE-469B-A2F9-63D43EC64545Q26830569-D45F8469-1E7B-4CF9-8680-CB715AF5F474Q27021438-9706248A-CC09-41B9-B106-1342B32F2F25Q28293910-F505804C-C75C-4D19-91B5-06A5112AA6F2Q28732041-5986C782-F386-4826-8139-9F9DA0B9A7CFQ29617758-1B40A6CB-350B-4B32-A98C-CA8C612A1CE3Q30478693-4A738776-E49C-4EED-BE11-71074946763FQ30583336-BB03DBC4-34D6-4DDF-BFCB-8E153A4F7385Q33269626-68381211-47FB-4168-B5FD-136A8F1319F9Q33395184-39602FD0-D0F0-4472-B099-45D067EE943AQ33544140-247C9D75-39F9-42B7-8450-166DD44216C4Q33610978-7CF3747F-56FE-4975-AE4C-BA393177CE4CQ33763221-7BB5C0CC-8B31-4419-A115-6FC64049D625Q33798949-4991BA92-7C79-4565-99D1-C5355FC52DE6Q33906477-DF9B705C-2F50-4372-B84E-3A642965FB2EQ33916422-489B7C5E-92B4-454C-A69C-D05BD89A00D2Q34158053-A8FE8B38-ABB4-4E40-998B-5608B498A9EEQ34383956-8B18B98D-8675-4418-8175-6A79E5137BADQ34544210-6FE90273-70BB-4617-B6B4-497958ADB394Q34786041-B7343AF0-A151-4E3A-A466-A416BB996ECBQ35056435-69DFB14C-A583-4036-B3B9-A464F65A901CQ35063491-11A701E6-2608-4E30-8C14-405C771A9C2FQ35098641-3E9CDBE6-890B-438E-8DF3-AB17B6F904F7Q35103561-07DF5048-5265-4026-8AA4-E7AA41DFEC0FQ35115469-35B30052-3D76-4B9B-9864-2B5D9D3C7AFFQ35116154-64325220-724B-40BC-AA83-1319B888D065Q35187593-0929ACA3-29F6-44B3-B5E3-21B4D8467075Q35189921-77F96E50-8894-48FB-8D04-8B9C3CEAB7D7Q35193348-CC3B1664-8141-49CC-8A73-027B02B96163Q35194110-7DA5219A-9D8B-459E-B2B1-DE92D03FA092Q35739625-A4ED0CC7-955F-44AB-925E-C79942EA4E04Q35748581-174B1188-EA0F-410F-A95C-49D547B080A7Q35755283-8A7EF544-ADC4-4F6E-B9FB-B4CFA71A1903Q35759924-17AA7522-A272-49A8-BEBC-41DD466674CDQ35850785-F61FB38A-71D6-489D-9717-746E0B41ABB7Q36097614-F5AC3176-24E9-4431-A24C-ECC73A208BCFQ36150816-BC5EB91B-D2F9-411B-A314-0F9677AC5D54Q36227849-25626CCF-0E4A-415A-B089-6793AECA226B
P2860
Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases
description
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
im März 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2002/03/01)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd op 2002/03/01)
@nl
наукова стаття, опублікована в березні 2002
@uk
مقالة علمية (نشرت في مارس 2002)
@ar
name
Inhibition of LFA-1/ICAM-1 and ...... mation and autoimmune diseases
@ast
Inhibition of LFA-1/ICAM-1 and ...... mation and autoimmune diseases
@en
Inhibition of LFA-1/ICAM-1 and ...... mation and autoimmune diseases
@nl
type
label
Inhibition of LFA-1/ICAM-1 and ...... mation and autoimmune diseases
@ast
Inhibition of LFA-1/ICAM-1 and ...... mation and autoimmune diseases
@en
Inhibition of LFA-1/ICAM-1 and ...... mation and autoimmune diseases
@nl
prefLabel
Inhibition of LFA-1/ICAM-1 and ...... mation and autoimmune diseases
@ast
Inhibition of LFA-1/ICAM-1 and ...... mation and autoimmune diseases
@en
Inhibition of LFA-1/ICAM-1 and ...... mation and autoimmune diseases
@nl
P2093
P2860
P3181
P356
P1476
Inhibition of LFA-1/ICAM-1 and ...... mation and autoimmune diseases
@en
P2093
Helena Yusuf-Makagiansar
Meagan E Anderson
Tatyana V Yakovleva
Teruna J Siahaan
P2860
P304
P3181
P356
10.1002/MED.10001
P577
2002-03-01T00:00:00Z